Robin Cornelissen discusses new agents developed for the treatment of NSCLC patients with EGFR or HER2 exon 20 insertion mutations, the role of next-generation sequencing in clinical practice, rare drivers of lung cancer with potential interest in the future, targeted approaches in the management of lung cancer as well as prognostic markers for survival or clinical decision making before extended pleurectomy and decortication surgery in malignant pleural mesothelioma.

Here is the full ESMO 2021 Lung Cancer report.